Petrus Trust Company LTA Purchases New Stake in Health Catalyst, Inc. $HCAT

Petrus Trust Company LTA acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 95,386 shares of the company's stock, valued at approximately $432,000. Petrus Trust Company LTA owned approximately 0.14% of Health Catalyst at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. SG Americas Securities LLC lifted its stake in Health Catalyst by 195.2% during the first quarter. SG Americas Securities LLC now owns 80,825 shares of the company's stock worth $366,000 after purchasing an additional 53,443 shares during the period. Invesco Ltd. lifted its position in Health Catalyst by 22.2% in the 1st quarter. Invesco Ltd. now owns 97,599 shares of the company's stock valued at $442,000 after acquiring an additional 17,725 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Health Catalyst in the 4th quarter valued at about $735,000. Whetstone Capital Advisors LLC bought a new stake in shares of Health Catalyst in the 1st quarter valued at about $7,724,000. Finally, Two Sigma Investments LP acquired a new position in Health Catalyst in the 4th quarter valued at about $496,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Stock Down 3.2%

Health Catalyst stock traded down $0.11 during trading hours on Friday, reaching $3.14. The stock had a trading volume of 511,496 shares, compared to its average volume of 727,373. Health Catalyst, Inc. has a 52 week low of $2.52 and a 52 week high of $9.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.83. The company has a market cap of $220.61 million, a price-to-earnings ratio of -2.08 and a beta of 1.53. The business's 50 day moving average price is $3.53 and its 200-day moving average price is $3.88.

Analyst Ratings Changes

Several brokerages recently commented on HCAT. Wells Fargo & Company dropped their price objective on shares of Health Catalyst from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Canaccord Genuity Group reduced their price objective on shares of Health Catalyst from $9.00 to $5.00 and set a "buy" rating for the company in a report on Friday, August 29th. Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a research report on Friday, August 29th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $4.00 target price (down previously from $9.00) on shares of Health Catalyst in a research note on Friday, August 8th. Finally, Citigroup cut shares of Health Catalyst from a "buy" rating to a "neutral" rating and cut their price target for the stock from $6.50 to $3.50 in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, Health Catalyst has an average rating of "Hold" and a consensus price target of $4.73.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.